Top Markets
#1 ADO Protocol ADO Protocol +328.56%
#2 GoPlus Security GoPlus Security +54.62%
#3 Starpower Starpower +45.32%
#4 Nockchain Nockchain +37.41%
#5 Verus Coin Verus Coin +33.47%
#6 Tutorial Tutorial +33.44%
#7 GAIB AID GAIB AID +24.67%
#8 The Black Bull The Black Bull +24.62%
#9 Chainflip Chainflip +21.84%
#10 peaq peaq +20.16%
Coin of the day
ADO Protocol ADO Protocol
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Delta-Fly Pharma, Inc. Delta-Fly Pharma, Inc.

Delta-Fly Pharma, Inc.

4598
Rangering i aksjer #32530
Delta-Fly Pharma, Inc., established in Tokushima, Japan, in 2010, is a... Delta-Fly Pharma, Inc., established in Tokushima, Japan, in 2010, is a biotechnology company focused on the development of innovative oncology drugs. Their comprehensive pipeline includes several drug candidates targeting various cancers. DFP-10917 is currently undergoing Phase III clinical evaluation in the United States and Phase I in Japan for relapsed/refractory acute myeloid leukemia. Another significant compound, DFP-14323, is in Phase III trials for lung cancer. The firm is also advancing DFP-17729 through Phase I/II studies for solid tumors. Furthermore, DFP-11207 has successfully completed its Phase I clinical trial for pancreatic cancer. For hematologic malignancies, DFP-14927 is in Phase I, while DFP-10825 is in preclinical development, targeting gastric and ovarian cancers.
Aksjekurs
$0.69158324
Markedsverdi
$9.84M
Endring (1 dag)
0.00%
Endring (1 år)
-84.15%
Land
JP
Handel Delta-Fly Pharma, Inc. (4598)

Kategori

Healthcare
Inntekter for Delta-Fly Pharma, Inc. (4598)
Inntekter i 2026 TTM: 0
Ifølge Delta-Fly Pharma, Inc. sine nyeste økonomiske rapporter er selskapets nåværende resultat 0. I 2026 hadde selskapet et resultat på 0, lik resultatet i 2026, som var 0. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Delta-Fly Pharma, Inc. fra 2026 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
Ikke nok data for de angitte datoene.
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE